Asset Details
Do you wish to reserve the book?
Metabolism of patupilone in patients with advanced solid tumor malignancies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Metabolism of patupilone in patients with advanced solid tumor malignancies
Do you wish to request the book?
Metabolism of patupilone in patients with advanced solid tumor malignancies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Metabolism of patupilone in patients with advanced solid tumor malignancies
2013
Overview
Summary
A phase 1, open-label, non-randomized, single center study was conducted to determine the pharmacokinetics, distribution, metabolism, elimination, and mass balance of patupilone in patients with advanced solid tumors. Five patients with advanced solid tumors received 10 mg/m
2
(1.1 MBq) of
14
C–radiolabeled patupilone at cycle 1 as a 20-minute intravenous infusion every 3 weeks until disease progression. Sequential samples of blood/plasma were taken for 3 weeks and urine and fecal samples were collected for seven days after the first dose of patupilone. Patupilone blood levels decreased rapidly after the infusion. The compound showed a large volume of distribution (V
ss
: 2242 L). The main radiolabeled component in blood was patupilone itself, accompanied by the lactone hydrolysis products that are unlikely to contribute to the pharmacological effect of patupilone. The blood clearance of patupilone was relatively low at 14 L/h. The administered radioactivity dose was excreted slowly (46 % of dose up to 168 h) but ultimately accounted for 91 % of the dose by extrapolation. The fecal excretion of radioactivity was 2–3 times higher than the urinary excretion consistent with hepato-biliary elimination. Three patients had progressive disease and two patients had stable disease as their best response. Patupilone was generally well tolerated in patients with advanced solid tumors with no newly occurring safety events compared to previous clinical studies. In adult solid tumor patients, intravenous radiolabeled patupilone undergoes extensive metabolism with fecal excretion of radioactive metabolites predominating over renal excretion.
Publisher
Springer US,Springer,Springer Nature B.V
Subject
/ Antineoplastic Agents - blood
/ Antineoplastic Agents - pharmacokinetics
/ Antineoplastic Agents - therapeutic use
/ Antineoplastic Agents - urine
/ Biological and medical sciences
/ Epothilones - pharmacokinetics
/ Epothilones - therapeutic use
/ Feces
/ Female
/ Humans
/ Male
/ Medicine
/ Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
/ Oncology
/ Patients
/ Pharmacology. Drug treatments
/ R&D
/ Studies
/ Surgery
/ Tubulin Modulators - pharmacokinetics
/ Tubulin Modulators - therapeutic use
/ Tumors
